Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A.W. Brown is active.

Publication


Featured researches published by A.W. Brown.


Journal of Heart and Lung Transplantation | 2018

Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis

S. Agbor-Enoh; Annette M. Jackson; I. Tunc; Gerald J. Berry; A.B. Cochrane; David Robert Grimm; Andrew Davis; Pali D. Shah; A.W. Brown; Yan Wang; Irina Timofte; Palak Shah; S. Gorham; Jennifer Wylie; Natalie Goodwin; Moon Kyoo Jang; A. Marishta; K. Bhatti; U. Fideli; Y. Yang; Helen Luikart; Z. Cao; Mehdi Pirooznia; J. Zhu; Charles Marboe; Aldo Iacono; S. Nathan; Jonathan B. Orens; H. Valantine; Kiran K. Khush

BACKGROUND Antibody-mediated rejection (AMR) often progresses to poor health outcomes in lung transplant recipients (LTRs). This, combined with the relatively insensitive clinical tools used for its diagnosis (spirometry, histopathology) led us to determine whether clinical AMR is diagnosed significantly later than its pathologic onset. In this study, we leveraged the high sensitivity of donor-derived cell-free DNA (ddcfDNA), a novel genomic tool, to detect early graft injury after lung transplantation. METHODS We adjudicated AMR and acute cellular rejection (ACR) in 157 LTRs using the consensus criteria of the International Society for Heart and Lung Transplantation (ISHLT). We assessed the kinetics of allograft injury in relation to ACR or AMR using both clinical criteria (decline in spirometry from baseline) and molecular criteria (ddcfDNA); percent ddcfDNA was quantitated via shotgun sequencing. We used a mixed-linear model to assess the relationship between and ddcfDNA levels and donor-specific antibodies (DSA) in AMR+ LTRs. RESULTS Compared with ACR, AMR episodes (n = 42) were associated with significantly greater allograft injury when assessed by both spirometric (0.1 liter vs -0.6 liter, p < 0.01) and molecular (ddcfDNA) analysis (1.1% vs 5.4%, p < 0.001). Allograft injury detected by ddcfDNA preceded clinical AMR diagnosis by a median of 2.8 months. Within the same interval, spirometry or histopathology did not reveal findings of allograft injury or dysfunction. Elevated levels of ddcfDNA before clinical diagnosis of AMR were associated with a concurrent rise in DSA levels. CONCLUSION Diagnosis of clinical AMR in LTRs lags behind DSA-associated molecular allograft injury as assessed by ddcfDNA.


Case Reports | 2018

Fungal thyroiditis in a lung transplant recipient

Christopher S. King; Stephen Clement; Shalika Katugaha; A.W. Brown

A 59-year-old man was admitted with 3 weeks of worsening shortness of breath 18 months after receiving a bilateral lung transplant for idiopathic pulmonary fibrosis. His immunosuppression included tacrolimus, everolimus and low-dose prednisone with no antifungal prophylaxis at the time of admission. CT chest revealed multiple, bilateral pulmonary nodules (figure 1—red arrows). CT-guided biopsy revealed fungal hyphae (figure 2). The initial CT and ultrasound of the neck at the onset of sore throat was negative; however, repeat CT neck for evolving neck pain and dysphasia during hospital course showed a mass-like lesion in the …


Journal of Heart and Lung Transplantation | 2018

High Body Mass Index is a Risk Factor for Acute Cellular Rejection in Lung Transplant Recipients

F.S. Nunes; Christopher S. King; Steven D Nathan; Margaret Fregoso; K. Ahmad; S. Aryal; A.W. Brown; Scott D. Barnett; Oksana A. Shlobin; A. Vester


Journal of Heart and Lung Transplantation | 2018

Antibody-mediated Rejection: Should We Wait for Clinical Diagnosis?

S. Agbor-Enoh; Annette M. Jackson; Gerald J. Berry; A.B. Cochrane; I. Tunc; Moon Kyoo Jang; K. Bhatti; A. Marishta; S. Gorham; Y. Yang; U. Fideli; J. Zhu; Mehdi Pirooznia; David Robert Grimm; Helen Luikart; Pali D. Shah; I. Timofte; Aldo Iacono; Z. Cao; A.W. Brown; Jonathan B. Orens; Charles Marboe; S. Nathan; Kiran K. Khush; H. Valantine


Journal of Heart and Lung Transplantation | 2018

Clinically-unrecognized Allograft Injury is Common After Lung Transplantion

S. Agbor-Enoh; I. Tunc; S. Gorham; Moon Kyoo Jang; U. Fideli; A. Marishta; J. Zhu; Mehdi Pirooznia; Y. Yang; Andrew Davis; David Robert Grimm; Z. Cao; Helen Luikart; Pali D. Shah; I. Timofte; A.W. Brown; Aldo Iacono; S. Nathan; Jonathan B. Orens; Kiran K. Khush; H. Valantine


Journal of Heart and Lung Transplantation | 2018

Is the New ISHLT Criteria for Pulmonary Antibody-mediated Rejection Also a Severity Indicator?

S. Agbor-Enoh; A.B. Cochrane; Annette M. Jackson; I. Tunc; Pali D. Shah; Z. Cao; A.W. Brown; I. Timofte; A. Marishta; Moon Kyoo Jang; S. Gorham; Y. Yang; U. Fideli; Aldo Iacono; S. Nathan; Jonathan B. Orens; H. Valantine


Journal of Heart and Lung Transplantation | 2018

Abnormal Invasive Pulmonary Hemodynamics Predict Outcomes in Exercising Patients

A. Jose; Christopher S. King; E. Welt; Oksana A. Shlobin; A.W. Brown; S. Aryal; Nargues Weir; S. Nathan


Journal of Heart and Lung Transplantation | 2018

Role of dd-cfDNA in Predicting Early Post-operative Course in Lung Transplant Recipients

A.W. Brown; S. Agbor-Enoh; Pali D. Shah; I. Timofte; Jonathan B. Orens; Aldo Iacono; M. Lemma; S. Barnett; F. Soares; S. Nathan; K. Ahmad; H. Valantine


Journal of Heart and Lung Transplantation | 2018

Elevated Donor-Derived Cell-Free DNA (ddcfDNA) as an Early Risk Factor for the Development and Persistence of De Novo Donor Specific HLA Antibody

Annette M. Jackson; A.B. Cochrane; S. Nathan; A.W. Brown; Pali D. Shah; Jonathan B. Orens; Aldo Iacono; I. Timofte; S. Agbor-Enoh; H. Valantine


Journal of Heart and Lung Transplantation | 2018

Predicting Risk of Early Readmission in Lung Transplant Recipients Using dd-cfDNA

K. Ahmad; S. Agbor-Enoh; Pali D. Shah; I. Timofte; Jonathan B. Orens; Aldo Iacono; M. Lemma; S. Aryal; A.B. Cochrane; F. Soares; S. Nathan; A.W. Brown; H. Valantine

Collaboration


Dive into the A.W. Brown's collaboration.

Top Co-Authors

Avatar

Oksana A. Shlobin

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

S. Nathan

Inova Fairfax Hospital

View shared research outputs
Top Co-Authors

Avatar

Aldo Iacono

University of Maryland

View shared research outputs
Top Co-Authors

Avatar

H. Valantine

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

S. Agbor-Enoh

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pali D. Shah

Johns Hopkins University

View shared research outputs
Researchain Logo
Decentralizing Knowledge